Article metrics

Download PDFPDF

Original research
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

 

Online download statistics by month:

Online download statistics by month: April 2022 to December 2022

AbstractFullPdf
Apr 2022476477196
May 2022334336134
Jun 202219518274
Jul 202215015051
Aug 202211110734
Sep 202220519771
Oct 202216116260
Nov 20229910048
Dec 202210710237
Total18381813705